Selected research
Industry Research
Purpura Therapy Drugs Industry Research Report 2026
Market perspective
The global Purpura Therapy Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Purpura Therapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Purpura Therapy Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Purpura Therapy Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Purpura Therapy Drugs include Ablynx NV, Bristol-Myers Squibb Company, Grifols Biologicals Inc, Hoffman-L Roche, Hovione, KM Biologics, Lee's Pharmaceutical Holdings Ltd, Omeros Corp and Pfizer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Purpura Therapy Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Purpura Therapy Drugs Market by Company
Ablynx NV
Bristol-Myers Squibb Company
Grifols Biologicals Inc
Hoffman-L Roche
Hovione
KM Biologics
Lee's Pharmaceutical Holdings Ltd
Omeros Corp
Pfizer Inc
Roch
Sanofi Winthrop Industrie S.A.
Amgen Inc
Biogen Inc
GlaxoSmithKline Plc
Novartis AG
Takeda
Purpura Therapy Drugs Segment by Type
Allergic Purpura
Thrombocytopenic Purpura
Purpura Therapy Drugs Segment by Application
Hospital Use
Clinic Use
Household
Others
Purpura Therapy Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Purpura Therapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Purpura Therapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Purpura Therapy Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Purpura Therapy Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Purpura Therapy Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Purpura Therapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Allergic Purpura
- Thrombocytopenic Purpura
Applications
- Hospital Use
- Clinic Use
- Household
- Others
Companies covered
- Ablynx NV
- Bristol-Myers Squibb Company
- Grifols Biologicals Inc
- Hoffman-L Roche
- Hovione
- KM Biologics
- Lee's Pharmaceutical Holdings Ltd
- Omeros Corp
- Pfizer Inc
- Roch
- Sanofi Winthrop Industrie S.A.
- Amgen Inc
- Biogen Inc
- GlaxoSmithKline Plc
- Novartis AG
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Purpura Therapy Drugs Market Size (2021-2032)
- 2.2.2 Global Purpura Therapy Drugs Sales (2021-2032)
- 2.2.3 Global Purpura Therapy Drugs Market Average Price (2021-2032)
- 2.3 Purpura Therapy Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Allergic Purpura
- 2.3.3 Thrombocytopenic Purpura
- 2.4 Purpura Therapy Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Use
- 2.4.3 Clinic Use
- 2.4.4 Household
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Purpura Therapy Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Purpura Therapy Drugs Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Purpura Therapy Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Purpura Therapy Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Purpura Therapy Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Purpura Therapy Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Purpura Therapy Drugs, Product Type & Application
- 3.8 Global Manufacturers of Purpura Therapy Drugs, Established Date
- 3.9 Global Purpura Therapy Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Ablynx NV
- 4.1.1 Ablynx NV Company Information
- 4.1.2 Ablynx NV Business Overview
- 4.1.3 Ablynx NV Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Ablynx NV Purpura Therapy Drugs Product Portfolio
- 4.1.5 Ablynx NV Recent Developments
- 4.2 Bristol-Myers Squibb Company
- 4.2.1 Bristol-Myers Squibb Company Company Information
- 4.2.2 Bristol-Myers Squibb Company Business Overview
- 4.2.3 Bristol-Myers Squibb Company Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Company Purpura Therapy Drugs Product Portfolio
- 4.2.5 Bristol-Myers Squibb Company Recent Developments
- 4.3 Grifols Biologicals Inc
- 4.3.1 Grifols Biologicals Inc Company Information
- 4.3.2 Grifols Biologicals Inc Business Overview
- 4.3.3 Grifols Biologicals Inc Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Grifols Biologicals Inc Purpura Therapy Drugs Product Portfolio
- 4.3.5 Grifols Biologicals Inc Recent Developments
- 4.4 Hoffman-L Roche
- 4.4.1 Hoffman-L Roche Company Information
- 4.4.2 Hoffman-L Roche Business Overview
- 4.4.3 Hoffman-L Roche Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hoffman-L Roche Purpura Therapy Drugs Product Portfolio
- 4.4.5 Hoffman-L Roche Recent Developments
- 4.5 Hovione
- 4.5.1 Hovione Company Information
- 4.5.2 Hovione Business Overview
- 4.5.3 Hovione Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hovione Purpura Therapy Drugs Product Portfolio
- 4.5.5 Hovione Recent Developments
- 4.6 KM Biologics
- 4.6.1 KM Biologics Company Information
- 4.6.2 KM Biologics Business Overview
- 4.6.3 KM Biologics Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 KM Biologics Purpura Therapy Drugs Product Portfolio
- 4.6.5 KM Biologics Recent Developments
- 4.7 Lee's Pharmaceutical Holdings Ltd
- 4.7.1 Lee's Pharmaceutical Holdings Ltd Company Information
- 4.7.2 Lee's Pharmaceutical Holdings Ltd Business Overview
- 4.7.3 Lee's Pharmaceutical Holdings Ltd Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lee's Pharmaceutical Holdings Ltd Purpura Therapy Drugs Product Portfolio
- 4.7.5 Lee's Pharmaceutical Holdings Ltd Recent Developments
- 4.8 Omeros Corp
- 4.8.1 Omeros Corp Company Information
- 4.8.2 Omeros Corp Business Overview
- 4.8.3 Omeros Corp Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Omeros Corp Purpura Therapy Drugs Product Portfolio
- 4.8.5 Omeros Corp Recent Developments
- 4.9 Pfizer Inc
- 4.9.1 Pfizer Inc Company Information
- 4.9.2 Pfizer Inc Business Overview
- 4.9.3 Pfizer Inc Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer Inc Purpura Therapy Drugs Product Portfolio
- 4.9.5 Pfizer Inc Recent Developments
- 4.10 Roch
- 4.10.1 Roch Company Information
- 4.10.2 Roch Business Overview
- 4.10.3 Roch Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Roch Purpura Therapy Drugs Product Portfolio
- 4.10.5 Roch Recent Developments
- 4.11 Sanofi Winthrop Industrie S.A.
- 4.11.1 Sanofi Winthrop Industrie S.A. Company Information
- 4.11.2 Sanofi Winthrop Industrie S.A. Business Overview
- 4.11.3 Sanofi Winthrop Industrie S.A. Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sanofi Winthrop Industrie S.A. Purpura Therapy Drugs Product Portfolio
- 4.11.5 Sanofi Winthrop Industrie S.A. Recent Developments
- 4.12 Amgen Inc
- 4.12.1 Amgen Inc Company Information
- 4.12.2 Amgen Inc Business Overview
- 4.12.3 Amgen Inc Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Amgen Inc Purpura Therapy Drugs Product Portfolio
- 4.12.5 Amgen Inc Recent Developments
- 4.13 Biogen Inc
- 4.13.1 Biogen Inc Company Information
- 4.13.2 Biogen Inc Business Overview
- 4.13.3 Biogen Inc Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Biogen Inc Purpura Therapy Drugs Product Portfolio
- 4.13.5 Biogen Inc Recent Developments
- 4.14 GlaxoSmithKline Plc
- 4.14.1 GlaxoSmithKline Plc Company Information
- 4.14.2 GlaxoSmithKline Plc Business Overview
- 4.14.3 GlaxoSmithKline Plc Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 GlaxoSmithKline Plc Purpura Therapy Drugs Product Portfolio
- 4.14.5 GlaxoSmithKline Plc Recent Developments
- 4.15 Novartis AG
- 4.15.1 Novartis AG Company Information
- 4.15.2 Novartis AG Business Overview
- 4.15.3 Novartis AG Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Novartis AG Purpura Therapy Drugs Product Portfolio
- 4.15.5 Novartis AG Recent Developments
- 4.16 Takeda
- 4.16.1 Takeda Company Information
- 4.16.2 Takeda Business Overview
- 4.16.3 Takeda Purpura Therapy Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Takeda Purpura Therapy Drugs Product Portfolio
- 4.16.5 Takeda Recent Developments
5 Global Purpura Therapy Drugs Market Scenario by Region
- 5.1 Global Purpura Therapy Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Purpura Therapy Drugs Sales by Region: 2021-2032
- 5.2.1 Global Purpura Therapy Drugs Sales by Region: 2021-2026
- 5.2.2 Global Purpura Therapy Drugs Sales by Region: 2027-2032
- 5.3 Global Purpura Therapy Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Purpura Therapy Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Purpura Therapy Drugs Revenue by Region: 2027-2032
- 5.4 North America Purpura Therapy Drugs Market Facts & Figures by Country
- 5.4.1 North America Purpura Therapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Purpura Therapy Drugs Sales by Country (2021-2032)
- 5.4.3 North America Purpura Therapy Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Purpura Therapy Drugs Market Facts & Figures by Country
- 5.5.1 Europe Purpura Therapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Purpura Therapy Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Purpura Therapy Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Purpura Therapy Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Purpura Therapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Purpura Therapy Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Purpura Therapy Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Purpura Therapy Drugs Market Facts & Figures by Country
- 5.7.1 South America Purpura Therapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Purpura Therapy Drugs Sales by Country (2021-2032)
- 5.7.3 South America Purpura Therapy Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Purpura Therapy Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Purpura Therapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Purpura Therapy Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Purpura Therapy Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Purpura Therapy Drugs Sales by Type (2021-2032)
- 6.1.1 Global Purpura Therapy Drugs Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Purpura Therapy Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Purpura Therapy Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Purpura Therapy Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Purpura Therapy Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Purpura Therapy Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Purpura Therapy Drugs Sales by Application (2021-2032)
- 7.1.1 Global Purpura Therapy Drugs Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Purpura Therapy Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Purpura Therapy Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Purpura Therapy Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Purpura Therapy Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Purpura Therapy Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Purpura Therapy Drugs Value Chain Analysis
- 8.1.1 Purpura Therapy Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Purpura Therapy Drugs Production Mode & Process
- 8.2 Purpura Therapy Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Purpura Therapy Drugs Distributors
- 8.2.3 Purpura Therapy Drugs Customers
9 Global Purpura Therapy Drugs Analyzing Market Dynamics
- 9.1 Purpura Therapy Drugs Industry Trends
- 9.2 Purpura Therapy Drugs Industry Drivers
- 9.3 Purpura Therapy Drugs Industry Opportunities and Challenges
- 9.4 Purpura Therapy Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst